Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder

International Clinical Psychopharmacology

Volumn 24, Issue 6, 2009, Pages 296-305

  Montgomery, Stuart A ^a   Fava, Maurizio ^b   Padmanabhan, Sudharshan K ^c   Guico Pabia, Christine J ^c   Tourian, Karen A ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c PFIZER INC   (United States)

Author keywords

Discontinuation symptoms; Discontinuation emergent signs and symptoms; Major depressive disorder; Selective serotonin reuptake inhibitors; Serotonin noreplnephrine reuptake inhibitors; Taper poststudy emergent adverse events

Indexed keywords

DESVENLAFAXINE; ANTIDEPRESSANT AGENT; CYCLOHEXANOL DERIVATIVE; O-DESMETHYLVENLAFAXINE;

ABNORMAL DREAMING; ADULT; AGED; ANXIETY DISORDER; ARTICLE; CHECKLIST; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERHIDROSIS; IRRITABILITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; PRIORITY JOURNAL; RELAPSE; SCORING SYSTEM; SHORT COURSE THERAPY; SIDE EFFECT; SYMPTOM; ADOLESCENT; DOSE RESPONSE; MIDDLE AGED; TIME; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; CLINICAL TRIALS AS TOPIC; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 73949088037     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32832fbb5a     Document Type: Article

References (42)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders. 4th ed.Washington, DC: American Psychiatric Association.
2. Baldwin DS, Cooper JA, Huusom AK, Hindmarch I (2006). A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 21:159-169.
3. Baldwin DS, Montgomery SA, Nil R, Lader M (2007). Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 10:73-84. (Pubitemid 46122754)
4. Black DW,Wesner R, Gabel J (1993). The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 54:146-149. (Pubitemid 23141517)
5. Blier P, Tremblay P (2006). Physiologic mechanisms underlying the antidepressant discontinuation syndrome. J Clin Psychiatry 67 (Suppl 4):8-13. (Pubitemid 43764532)
6. Boyer P, Montgomery S, Lepola U, Germain J-M, Brisard C, Ganguly R, et al. (2008). Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol 23:243-253.
7. Coupland NJ, Bell CJ, Potokar JP (1996). Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 16:356-362.
8. Dallal A, Chouinard G (1998).Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine. J Clin Psychopharmacol 18:343-344. (Pubitemid 28353880)
9. DeMartinis NA, Yeung PP, Entsuah R, Manley AL (2007). A double-blind, placebocontrolled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry 68:677-688. (Pubitemid 46841850)
10. Edwards JG, Anderson I (1999). Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 57:507-533.
11. Fava M (2006). Prospective studies of adverse events related to antidepressant discontinuation. J Clin Psychiatry 67 (Suppl 4):14-21.
12. Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF (1997). Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry 154:1760-1762. (Pubitemid 27516598)
13. Feiger AD, Tourian K, Rosas G, Padmanabhan K (2009). A placebo-controlled efficacy and safety study of a flexible dose of desvenlafaxine in outpatients with major depressive disorder. CNS Spectr 14:41-50.
14. GlaxoSmithKline (2006). Paroxetine [package insert]. Research Triangle Park, NC.
15. Haddad P (1997). Newer antidepressants and the discontinuation syndrome. J Clin Psychiatry 58 (Suppl 7):17-21.
16. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg. Psychiatry 23:56-62.
17. Hindmarch I, Kimber S, Cockle SM (2000). Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol 15:305-318. (Pubitemid 30812583)
18. Judge R, Parry MG, Quail D, Jacobson JG (2002). Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol 17:217-225.
19. Lejoyeux M, Ades J (1997). Antidepressant discontinuation: a review of the literature. J Clin Psychiatry 58 (Suppl 7):11-15.
20. Lieberman DZ, Montgomery SA, Tourian KA, Brisard C, Rosas G, Padmanabhan K, et al. (2008). A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. Int Clin Psychopharmacol 23:188-197.
21. Liebowitz M, Yeung PP, Entsuah R (2007). A randomized, double-blind, placebocontrolled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. J Clin Psychiatry 68:1663-1672. (Pubitemid 350247495)
22. Liebowitz M, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA (2008). Efficacy, safety, and tolerability of desvenlafaxine 50 mg/d and 100 mg/d in outpatients with major depressive disorder. Curr Med Res Opin 24:1877-1890.
23. Lipman RS (1982). Differentiating anxiety and depression in anxiety disorders: use of rating scales. Psychopharmacol Bull 18:69-77. (Pubitemid 13223885)
24. Mallya G, White K, Gunderson C (1993). Is there a serotonergic withdrawal syndrome? Biol Psychiatry 33:851-852.
25. Michelson D, Fava M, Amsterdam J, Apter J, Londborg P, Tamura R, et al. (2000). Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. Br J Psychiatry 176:363-368. (Pubitemid 30204663)
26. Montgomery SA, Åsberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
27. Montgomery SA, Huusom AK, Bothmer J (2004a). A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 50:57-64. (Pubitemid 38721171)
28. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I (2004b). Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 19: 271-280. (Pubitemid 39141943)
29. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM (1991). Biochemical, neurophysiological, and behavioral effects of Wy-45 233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 23:191-199.
30. Perahia DG, Kajdasz DK, Desaiah D, Haddad PM (2005). Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord 89:207-212. (Pubitemid 41740850)
31. Price JS, Waller PC, Wood SM, MacKay AV (1996). A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 42:757-763.
32. Raskin A, Schulterbrandt J, Reatig N, McKeon JJ (1969). Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives. J Nerv Ment Dis 148:87-98.
33. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB (1998). Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 44:77-87. (Pubitemid 28305526)
34. Schatzberg AF, Haddad P, Kaplan EM, Lejoyeux M, Rosenbaum JF, Young AH, et al. (1997). Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. Discontinuation Consensus Panel. J Clin Psychiatry 58 (Suppl 7):5-10.
35. Schatzberg AF, Blier P, Delgado PL, Fava M, Haddad PM, Shelton RC (2006). Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. J Clin Psychiatry 67 (Suppl 4):27-30. (Pubitemid 43764535)
36. Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain J-M, Tourian KA (2007). A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol 22:338-347. (Pubitemid 47530838)
37. Shelton RC (2006). The nature of the discontinuation syndrome associated with antidepressant drugs. J Clin Psychiatry 67 (Suppl 4):3-7. (Pubitemid 43764531)
38. Sir A, D'Souza RF, Uguz S, George T, Vahip S, Hopwood M, et al. (2005). Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 66:1312-1320. (Pubitemid 41546512)
39. Terra JL, Montgomery SA (1998). Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol 13:55-62. (Pubitemid 28218515)
40. Tint A, Haddad PM, Anderson IM (2008). The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol 22:330-332. (Pubitemid 351847442)
41. Warner CH, Bobo W, Warner C, Reid S, Rachal J (2006). Antidepressant discontinuation syndrome. Am Fam Physician 74:449-456.
42. Zajecka J, Tracy KA, Mitchell S (1997). Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review. J Clin Psychiatry 58:291-297 (Pubitemid 27362484)